Trials / Completed
CompletedNCT02994394
A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
To assess the bioequivalence of OPC-41061 OD tablets and OPC-41061 conventional tablets at 15 and 30 mg in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-41061 |
Timeline
- Start date
- 2017-01-06
- Primary completion
- 2017-02-28
- Completion
- 2017-02-28
- First posted
- 2016-12-15
- Last updated
- 2021-06-28
- Results posted
- 2021-06-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02994394. Inclusion in this directory is not an endorsement.